Global X Data Center & Digital Infra ETF vs TG Therapeutics Inc — how do they compare? Global X Data Center & Digital Infra ETF trades at $27.65 (market cap $2.04B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4× Global X Data Center & Digital Infra ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Global X Data Center & Digital Infra ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 15 Days and TG Therapeutics Inc for 16 Days on average.
| DTCR | TGTX | |
|---|---|---|
Market Cap | $2.04B | $8.16B |
Volume | 899,532 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $59.06 |
52-Week Low | $19.73 | $26.94 |
Typical Hold Time | 15 Days | 16 Days |
Enterprise Value | — | $8.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →